ReviewStem cell research & therapy2025
Exploring MSC and HSPC interactions: new frontiers in hematopoiesis and transplant medicine.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Article
- Emerging trends in bone marrow organoid research: From hematopoietic microenvironment reconstruction to translational and regenerative theranostic applications.Theranostics · 2026Review
- The anti-inflammatory effects of mesenchymal stem cells and their research progress in hematopoietic stem cell transplantation: A comprehensive review.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stromal cells (MSCs) play a critical role in supporting hematopoietic stem and progenitor cells (HSPCs) within the bone marrow (BM) niche by providing a specialized extracellular matrix and essential signaling cues. Through the secretion of key ECM proteins and cell adhesion molecules, MSCs regulate HSPC proliferation, differentiation, homing, retention, and maintain their quiescence necessary for effective hematopoiesis. Understanding the intricate dynamics between MSCs and HSPCs in the BM is essential for advancing HSPC-based therapies. Targeting niche components, such as ECM proteins and CAMs, can enable HSPC expansion and engraftment, benefiting hematopoietic stem cell transplantation and gene therapy outcomes. In this review, we provide an overview of the niche components involved in MSCs-HSPCs interactions and its co-culture in improving the therapeutic outcomes, discuss existing challenges and propose possible solutions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.